THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY

被引:140
作者
BALIAN, JD
SUKHOVA, N
HARRIS, JW
HEWETT, J
PICKLE, L
GOLDSTEIN, JA
WOOSLEY, RL
FLOCKHART, DA
机构
[1] GEORGETOWN UNIV, MED CTR, DEPT MED, DIV CLIN PHARMACOL, WASHINGTON, DC 20007 USA
[2] GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20007 USA
[3] US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA
[4] NATL CTR HLTH STAT, HYATTSVILLE, MD 20782 USA
[5] NIEHS, RES TRIANGLE PK, NC 27709 USA
关键词
D O I
10.1016/0009-9236(95)90229-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We compared omeprazole and mephenytoin as probes for the CYP2C19 metabolic polymorphism, Single oral doses of omeprazole (20 mg) or mephenytoin (100 mg) were administered at least 1 week apart to 167 healthy volunteers, Mephenytoin metabolism was measured using the amount of 4'-hydroxymephenytoin and the S/R ratio of mephenytoin in an 8-hour urine collection, Omeprazole hydroxylation was measured using the ratio of omeprazole to 5'-hydroxyomeprazole in serum 2 hours after dosing, All three methods separated poor- or extensive-metabolizer phenotypes with complete concordance, Omeprazole hydroxylation correlated with the S/R ratio of mephenytoin in extensive metabolizers (r(2) = 0.681; P < 0.001), Genotyping tests showed that six poor metabolizers of omeprazole were homozygous for a single base pair mutation in exon 5 of CYP2C19. These results support the hypothesis that omeprazole 5'-hydroxylation cosegregates with the CYP2C19 metabolic polymorphism.
引用
收藏
页码:662 / 669
页数:8
相关论文
共 38 条
[1]  
ADAMS MH, 1988, CLIN PHARMACY, V7, P725
[2]   CLINICAL CONSEQUENCES OF POLYMORPHIC DRUG OXIDATION [J].
ALVAN, G .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1991, 5 (03) :209-228
[3]   POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS [J].
ANDERSSON, T ;
REGARDH, CG ;
LOU, YC ;
ZHANG, Y ;
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1992, 2 (01) :25-31
[4]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :597-604
[5]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[6]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[7]   ENANTIOSELECTIVE AMITRIPTYLINE METABOLISM IN PATIENTS PHENOTYPED FOR 2 CYTOCHROME-P450 ISOZYMES [J].
BREYERPFAFF, U ;
PFANDL, B ;
NILL, K ;
NUSSER, E ;
MONNEY, C ;
JONZIERPEREY, M ;
BAETTIG, D ;
BAUMANN, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) :350-358
[8]   GENETICALLY-DETERMINED DEBRISOQUINE OXIDATION CAPACITY IN BLADDER-CANCER [J].
CARTWRIGHT, RA ;
PHILIP, PA ;
ROGERS, HJ ;
GLASHAN, RW .
CARCINOGENESIS, 1984, 5 (09) :1191-1192
[9]  
CURIPEDROSA R, 1993, ISSX P, V3, P46
[10]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594